TIDMMTPH

RNS Number : 3138P

Midatech Pharma PLC

17 February 2021

17 February 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Exercise of Warrants and Issue of Equity

Total Voting Rights

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to certain US investors 61,363 American Depositary Shares ("ADSs"), representing 306,815 ordinary shares of 0.1p each in the Company ("New Ordinary Shares"), in connection with the exercise of pre-existing warrants by such investors at an exercise price of $2.0625 per ADS. Each ADS represents five ordinary shares. The gross proceeds received by the Company from the exercise of these warrants is $126,561.

Application has been made for admission of 306,815 New Ordinary Shares to trading on the AIM Market of the London Stock Exchange ("Admission"), which is expected to become effective at 8.00am on or around 19 February 2021. The New Ordinary Shares will rank pari passu with the existing ordinary shares.

The Company's issued share capital following the issue of equity noted above, will comprise 63,380,667 Ordinary Shares each with voting rights. The Company does not hold any shares in treasury. This figure of 63,380,667 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)1235 888300 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 Tel: +44 (0)20 7886 2500 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Megan Paul 
  Tel: (646) 653 7034 
  Email: mpaul@edisongroup.com 
            About Midatech Pharma PLC 
              Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
              MTP) is a drug delivery technology company focused on improving 
              the bio-delivery and bio-distribution of medicines. The Company 
              combines approved and development medications with its proprietary 
              and innovative drug delivery technologies to provide compelling 
              products that have the potential to powerfully impact the lives 
              of patients. 
 
              The Company has developed three in-house technology platforms, 
              each with its own unique mechanism to improve delivery of medications 
              to sites of disease. All of the Company's technologies have successfully 
              entered human use in the clinic, providing important validation 
              of the potential for each platform: 
 
               *    Q-Sphera(TM) platform: a disruptive micro-technology 
                    used for sustained release to prolong and control the 
                    release of therapeutics over an extended period of 
                    time (from weeks to months). 
 
 
               *    MidaSolve(TM) platform: an innovative nanotechnology 
                    used to dissolve insoluble drugs so that they can be 
                    administered in liquid form directly and locally into 
                    tumours. 
 
 
               *    MidaCore(TM) platform: a leading-edge nanotechnology 
                    used for targeting medications to sites of disease. 
 
 
 
              The platform nature of the technologies offers the potential to 
              develop multiple drug assets rather than being reliant on a limited 
              number of programmes. Midatech's technologies are supported by 
              36 patent families including 120 granted patents and an additional 
              70 patent applications. Midatech's headquarters and R&D facility 
              is in Cardiff, UK. For more information please visit www.midatechpharma.com 
 
  Forward-Looking Statements 
 
  Certain statements in this press release may constitute "forward-looking 
  statements" within the meaning of legislation in the United 
  Kingdom and/or United States Private Securities Litigation 
  Reform Act. All statements contained in this press release 
  that do not relate to matters of historical fact should be 
  considered forward-looking statements. 
 
  Reference should be made to those documents that Midatech 
  shall file from time to time or announcements that may be 
  made by Midatech in accordance with the London Stock Exchange 
  AIM Rules for Companies ("AIM Rules"), the Disclosure and 
  Transparency Rules ("DTRs") and the rules and regulations 
  promulgated by the US Securities and Exchange Commission, 
  which contains and identifies other important factors that 
  could cause actual results to differ materially from those 
  contained in any projections or forward-looking statements. 
  These forward-looking statements speak only as of the date 
  of this announcement. All subsequent written and oral forward-looking 
  statements by or concerning Midatech are expressly qualified 
  in their entirety by the cautionary statements above. Except 
  as may be required under the AIM Rules or the DTRs or by relevant 
  law in the United Kingdom or the United States, Midatech does 
  not undertake any obligation to publicly update or revise 
  any forward-looking statements because of new information, 
  future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEEAFAKFFLFEAA

(END) Dow Jones Newswires

February 17, 2021 02:00 ET (07:00 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.